“Arbitrary upper age limits for trial entry are almost never justified,” says FDA, which has renewed its efforts to include older adults in clinical trials and tackle some of the key enrollment challenges.
While senior citizens consume roughly one third of all medications – and make up only 13% of the population – factors that complicate geriatric clinical trials leave gaps in knowledge and developments.